A Phase 1/2a Study of BMS-986178 Administered Alone and in Combination With Nivolumab or Ipilimumab in Advanced Solid Tumors

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol Myers Squibb CA012-004 (OX-40)

To Learn More Call
201-510-0910